Literatuur

• American Psychiatric Association (2004). FDA committee urges new warning on antidepressants for pregnancy. Psychiatric News, 39, 33.  
• Andersson, L., Sundström-Poromaa, I., Wulff, M., Aström, M., & Bixo, M. (2006). Depression and anxiety during pregnancy and six months postpartum: a follow-up study. Acta Obstet Gynecol Scand, 85, 937-44.  
• Andres, R.L, & Day, M.C.(2000). Perinatal complications associated with maternal tobacco use. Seminars on Neonatology, 5, 231-41.  
• Austin, M.P., et al. (2008). Brief antenatal cognitive behaviour therapy group intervention for the prevention of postnatal depression and anxiety: a randomised controlled trial. Journal of Affective Disorders,105, 35-44.
• Chambers, C.D., Hernandez-Diaz, S., Van Marter, L.J., Werler, M.M., Louik, C., Jones, K.L., & Mitchell, A.A. (2006). Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New England Journal of Medicine, 354,  579-87.
• Bar-Oz B., Einarson T., Einarson A., Boskovic, R., O'Brien, L., Malm, H., Bérard, A., & Koren, G. (2007). Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clinical Therapy, 29, 918-26.
• Beck, C.T. (2001) Predictors of postpartum depression: an update. Nursing Research, 50, 275–85.
• Beck, A.T. (2005). The current state of cognitive therapy: a 40-year retrospective. Archives of General Psychiatry, 62, 953-959.
• Bennett, H.A., Einarson, A., Taddio, A., Koren, G., & Einarson, T.R. (2004). Depression during Pregnancy: overview of child factors. Clinical Drug Investigation, 24, 157-159.
• Bledsoe, S.E, & Grote, N.K. (2006).Treating depression during pregnancy and postpartum: a preliminary meta-analysis. Research on Social Work Practice, 16, 109-120.
• Costei, A.M., Kozer, E., Ho, T., Ito, S., & Koren, G. (2002). Perinatal outcome following third trimester exposure to paroxetine. Archives of Pediatric and Adolescent Medicine, 156,1129-1132.
• Croen, L.A., Yoshida, C.K., Odouli, R., & Newman, T.B. (2005). Neonatal hyperbilirubinemia and risk of autism spectrum disorders. Pediatrics, 115, 135-138.
• Cuijpers, P., Straten, A. van, Warmerdam, L., & Andersson, G. (2009). Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of  depression: a meta-analysis. Depression and Anxiety, 26, 279-288.  
• Cummings, E.M., & Davies, P.T. (1994). Maternal depression and child development. Journal of Child Psychololgy and Psychiatry, 35, 73-112.
• Davis, E.P., et al., (2007). Prenatal exposure to maternal depression and cortisol influences infant temperament. Journal of the.American Academy of Child and Adolescent Psychiatry, 46, 737-746.  
• Dobson, K.S. (1989). A meta-analysis of the efficacy of cognitive therapy for depression. Journal of Consulting and Clinical Psychology, 57, 414-419.  
• Dubnov-Raz, G., Juurlin, D.N, Fogelman R, Merlob P, Ito S, Koren G, & Finkelstein, Y. (2008). Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics, 122, 710-715.
• Evans, J., et al., (2001). Cohort study of depressed mood during pregnancy and after child birth. BMJ, 323, 257-60.
• Felice, E., Saliba, J., Grech, V., Cox, J., & Calleja, N. (2007). Antenatal psychiatric morbidity in Maltese women. General Hospital Psychiatry, 29, 501-5.
• Ferreira, E., Carceller, A.M., Agogué, C., Martin, B.Z., St-André, M., Francoeur, D., & Bérard, A. (2007). Effects of selective serotonin reuptake inhibitors and venlafaxine during  pregnancy in term and preterm neonates. Pediatrics,119, 52-59.
• Gaynes, B.N., Gavin, N., Meltzer-Brody, S., Lohr, K.N., Swinson, T., Gartlehner, G., Brody, S., & Miller, W.C. (2005). Perinatal depression: prevalence, screening accuracy, and  screening outcomes. Evid Rep Technol Assess (Summ), 119, 1-8.
• Gloaguen, V., Cottraux, J., Cucherat, M., & Blackburn Y-M. (1989). A meta-analysis of the effects of cognitive therapy in depressed patients. Journal of Affective Disorders,   49, 59-72.
• Haddad, P.M., Pal, B.R., Clarke, P., Wieck, A., & Sridhiran, S. (2005). Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? Journal of Psychopharmacology,19, 554-7.
• Herbst, F., & Gortner, L. (2003). Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy? Zeitschrift für Geburtshilfe und Neonatologie,   207, 232-234.
• Huizink, A.C., & Mulder, E.J. (2006). Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. Neuroscience and Biobehavioral Review, 30, 24-41.  
• Laine, K., Heikkinen, T., Ekblad, U., & Kero, P. (2003). Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns  and cord blood monoamine and prolactin concentrations. Archives of General Psychiatry, 60, 720-726.  
• Maki, P. et al. (2003). Criminality in the offspring of antenatally depressed mothers: a 33-year follow-up of the Northern Finland 1966 Birth Cohort. Journal of Affective Disorders, 74, 273-8.
• Marcus, S.M., Flynn, H.A., Blow, F.C., & Barry, K.L. (2003). Depressive symptoms among pregnant women screened in obstetrics settings. Journal of Womens Health ,12, 373-80.
• Malm, H., Klaukka, T., & Neuvonen, P.J. (2005). Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstetrics and Gynecology, 106, 1289-1296.
• Martins, C., & Gaffan, E.A. (2000). Effects of early maternal depression on patterns of infant-mother attachment: a meta-analytic investigation. Journal of Child Psychology and Psychiatry, 41, 737-746.
• Misri, S., & Kendrick, K. (2007). Treatment of perinatal mood and anxiety disorders: A review. Canadian Journal of Psychiatry, 52, 489-498.
• Murray,  L.,  Fiori-Cowley,  A.,  Hooper,  R.,  &  Cooper,  P.  (1996).  The  impact  of  postnatal depression and associated adversity on early mother-infant interactions and later  infant outcome. Child Development, 67, 2512-2526.
• Oberlander, T.F., Bonaguro, R.J., Misri, S., Papsdorf, M., Ross, C.J., & Simpson, E.M. (2008). Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse  neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Molecular Psychiatry,13, 65-73.
• Oberlander, T.F, Warburton, W., Misri, S., Aghajanian, J., & Hertzman, C. (2006). Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Archives of General Psychiatry, 63, 898-906.
• O'Connor, T.G., Heron, J., & Glover, V. (2002). Antenatal anxiety predicts child behavioral/emotional problems independently of postnatal depression. Journal of the American  Academy of Child and Adolescent Psychiatry, 41, 470-477.
• O'Hara, M.W., & Swain, A.M. (1996). Rates and risk of postpartum depression—a meta analysis. International Review of Psychiatry, 8, 37–54.
• O'Keane, V., & Marsh, M.S. (2007). Depression during pregnancy. BMJ, 334,1003-1005.
• Radke-Yarrow,  M.,  Cummings,  E.M.,  Kuczynski,  L.,  &  Chapman,  M.  (1985).  Patterns  of attachment in two- and three-year-olds in normal families and families with parental depression. Child Development, 56, 884-93.
• Rahman, A., Malik, A., Sikander, S., Roberts, C., & Creed F. (2008). Cognitive behaviour therapy-based intervention by community health workers for mothers with depression and their infants in rural Pakistan: a cluster-randomised controlled trial. Lancet,  372, 902-909.
• Robertson, E., Grace, S., Wallington, T., & Stewart, D.E. (2004). Antenatal risk factors for postpartum depression: a synthesis of recent literature. General Hospital Psychiatry,   26, 289–295
• Schwartz, P.J., Locati, E.H., Napolitano, C., & Priori, S.G. (1995). The long QT syndrome. In: D.P. Zipes & J. Jalife (Eds.). Cardiac Electrophysiology: From Cell to Bedside. (2nd ed.) Philadelphia, PA: Saunders, 788 –811.
• Stewart, D.E. (2006). Perinatal depression. General Hospital Psychiatry, 28, 1-2.  
• Stowe, Z.N., & Nemeroff, C.B. (1995). Women at risk for postpartum onset major depression. American Journal of Obstetrics and Gynecology, 173, 639-45.
• Simon, G.E., Cunningham, M.L., & Davis, R.L. (2002). Outcomes of prenatal antidepressant exposure. American Journal of Psychiatry, 159, 2055–2061.
• Suri, R., Altshuler, L., Hellemann, G., Burt, V.K., Aquino, A., & Mintz, J. (2007). Effects of antenatal depression and antidepressant treatment on gestational age at birth and  risk of preterm birth. American Journal of Psychiatry,164, 1206-1213.  
• Talge, N.M., Neal, C., & Glover, V. (2007). Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? Journal of Child Psychology and Psychiatry, 48, 245-261.
• Tixier, H., Feyeux, C., Girod, S., Thouvenot, S., Morisse, M., Douvier, S, & Sagot, P. (2008). Acute voluntary intoxication with selective serotonin reuptake inhibitors during the  third trimester of pregnancy: therapeutic management of mother and fetus. American Journal of Obstetrics and Gynecology, 199, e9-e12.
• Van den Bergh, B.R., et al. (2005). Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A  review. Neuroscience and Biobehavioral Review, 29, 237-58.
• Wampold, B.E., Minami, T., Baskin, T.W., & Tierney, S.C. (2002). A meta-(re)analysis of the effect of cognitive therapy versus 'other therapies' for depression. Journal of Affective Disorders, 68, 159-165.
• Williams, J.H.G., & Ross, L. (2006). Consequences of prenatal toxin exposure for mental health in children and adolescents: A systematic review. European Child and Adolescent Psychiatry, 16, 243-253.